Danaher Corporation vs Manulife Financial Corporation — how do they compare? Danaher Corporation trades at $219.58 (market cap $152.87B), while Manulife Financial Corporation trades at $42.32 (market cap $69.48B). The key difference: Danaher Corporation is far larger — about 2.2× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Manulife Financial Corporation for 119 Days on average.
| DHR | MFC | |
|---|---|---|
Market Cap | $152.87B | $69.48B |
Volume | 5,228,698 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $242.05 | $44.77 |
52-Week Low | $161.91 | $31.64 |
Typical Hold Time | 69 Days | 119 Days |
Enterprise Value | $175.08B | $64.75B |
Dividend Yield | 0.74% | 3.23% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
MFC trades at $42.33, up 1.58% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $53.01B in 2025 to projected $57.5B in 2026, with net income margins around 11%. Recent institutional investments from Bank of America and executive appointments signal confidence. However, the stock trades above the $34.24 consensus price target, suggesting limited near-term upside.
The outlook remains mixed with solid fundamentals but valuation concerns. Investment opportunity lies in continued Asia growth and insurance sales momentum, while risks include premium valuation and potential earnings volatility. Analyst consensus leans bullish with 57% buy ratings, but technical indicators warn of near-term pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →